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Abstract
The prevalence of transmitted drug resistance (TDR) in antiretroviral therapy (ART)-naïve
individuals remains stable in most developed countries despite a decrease in the prevalence
of acquired drug resistance. This suggests that persistence and further transmission of HIV-1
that encodes transmitted drug resistance mutations (TDRMs) is occurring in ART-naïve indi-
viduals. In this study, we analysed the prevalence and persistence of TDRMs in the protease
and reverse transcriptase-sequences of ART-naïve patients within the German HIV-1 Sero-
converter Study Cohort who were infected between 1996 and 2017. The prevalence of
TDRMs and baseline susceptibility to antiretroviral drugs were assessed using the Stanford
HIVdb list and algorithm. Mean survival times of TDRMs were calculated by Kaplan-Meier
analysis. The overall prevalence of TDR was 17.2% (95% CI 15.7–18.6, N = 466/2715).
Transmitted NNRTI resistance was observed most frequently with 7.8% (95% CI 6.8–8.8), fol-
lowed by NRTI resistance (5.0%, 95% CI 4.2–5.9) and PI resistance (2.8%, 95% CI 2.2–3.4).
Total TDR (OR = 0.89, p = 0.034) and transmitted NRTI resistance (OR = 0.65, p = 0.000)
decreased between 1996 and 2017 but has remained stable during the last decade. Viral sus-
ceptibility to NNRTIs (6.5%-6.9% for individual drugs) was mainly reduced, while <3% of the
recommended NRTIs and PIs were affected. The longest mean survival times were calculated
for the NNRTI mutations K103N (5.3 years, 95% CI 4.2–5.6) and E138A/G/K (8.0 years, 95%
CI 5.8–10.2 / 7.9 years, 95% CI 5.4–10.3 / 6.7 years, 95% CI 6.7–6.7) and for the NRTI muta-
tion M41L (6.4 years, 95% CI 6.0–6.7).The long persistence of single TDRMs indicates that
onward transmission from ART-naïve individuals is the main cause for TDR in Germany.
Transmitted NNRTI resistance was the most frequent TDR, showing simultaneously the high-
est impact on baseline ART susceptibility and on TDRMs with prolonged persistence. These
results give cause for concern regarding the use of NNRTI in first-line regimens.







Citation: Machnowska P, Meixenberger K, Schmidt
D, Jessen H, Hillenbrand H, Gunsenheimer-
Bartmeyer B, et al. (2019) Prevalence and
persistence of transmitted drug resistance
mutations in the German HIV-1 Seroconverter
Study Cohort. PLoS ONE 14(1): e0209605. https://
doi.org/10.1371/journal.pone.0209605
Editor: Orna Mor, State of Israel Ministry of Health,
ISRAEL
Received: August 7, 2018
Accepted: December 7, 2018
Published: January 16, 2019
Copyright: © 2019 Machnowska et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files. Sequences are available at GenBank
(MH470511-MH472562; KX465238-KX467180;
KJ769682-KJ771884).
Funding: The German Seroconverter Study was
partially funded by the Federal Ministry of Health
(BMG) and the Federal Ministry of Education and
Research (BMBF). The funders had no role in study
design, data collection and analysis, decision to
Introduction
Globally, 36.7 million people are currently living with HIV. During the last 20 years, antiretroviral
therapy (ART) has been massively scaled up and, as a result, the number of new HIV-infections
has fallen by 35% since 2000 [1]. However, selective pressure from antiretroviral drugs promotes
the emergence of HIV drug resistance mutations (DRM), which can compromise successful treat-
ment. HIV-1 resistance is classified as ’primary’ when there is no history of ART or as ’secondary’,
when mutations emerge during ART. However, both forms of resistance are associated with a
delay in virologic suppression and an increased risk of virologic failure and onward transmission
[2, 3]. In individuals receiving ART, drug resistant viruses evolve from wild-type viruses and
coexist in a mixture of genetic variants [4]. As most drug resistance mutations impair viral fitness,
replacement of the drug resistant virus with a wild-type variant in the absence of drug pressure
can be advantageous for the pathogen [5–7]. Interruption of ART therefore rapidly leads to
reemergence of fitter wild-type variants [8]. However, transmitted drug resistance (TDR) differs
fundamentally from acquired drug resistance (ADR) because the wild-type virus is not archived
in these individuals. The emergence of a wild-type variant therefore depends on the number of
back mutations required, the relative fitness of mutant and wild-type virus, the rate of viral turn-
over and the presence of compensatory mutations [9]. The surveillance of transmitted drug resis-
tance mutations (TDRMs) is generally based on the surveillance drug resistance mutations
(SDRMs) list published by Bennett et al. in 2009, as recommended by the World Health Organi-
zation (WHO) [10]. However, the landscape of antiretrovirals is changing continuously and new
mutations such as E138A/G/K/Q/R (that confers resistance to the NNRTI rilpivirine (RPV),
approved in 2011) are therefore not covered by this list. Furthermore, mutations at subtype-spe-
cific polymorphic positions are excluded from the WHO SDRM list, despite a number of such
mutations contributing substantially to drug resistance. In our study, the analysis of TDRMs was
therefore based on the Stanford HIVdb SDRM list, which is updated regularly and includes all
mutations in the WHO SDRM list apart from F53Y and V85I in protease [11, 12].
One aspect of TDR that is rarely studied is the long-term persistence of drug-resistant HIV-
1 in ART-naïve individuals. TDRMs can persist significantly longer than acquired DRMs in
the infected person, even in the absence of selective drug pressure [13, 14]. Information con-
cerning the long-term persistence of TDRMs in the absence of drug pressure is limited because
only a relatively small number of individuals in study cohorts elect to refuse ART upon diag-
nosis. However, the few existing studies do show that the periods of individual TDRM persis-
tence are highly variable and that TDRMs can persist for several years [15–17]. This further
supports the hypothesis that TDR is driven mainly by onward transmission from ART-naïve
individuals rather than from patients with a history of ART [18–23].
The aim of our study was to gain insight into the prevalence of TDRMs in light of the
changing landscape of HIV-1 subtypes in the German HIV-1 Seroconverter Study Cohort
between 1996 and 2017 and to assess the proportion of study patients potentially at risk of
ART-failure due to these TDRMs. We also analysed the long-term persistence of individual
TDRMs in ART-naïve study patients. Compared to previously published analyses, our study
has one of the largest sample sizes, allowing a more detailed insight into the persistence of
TDRMs in the absence of selective drug pressure to be formed.
Materials and methods
Study population
The German HIV-1 Seroconverter Study is a nationwide, multicenter, open, prospective,
long-term observational cohort study in which the date of HIV-1 seroconversion is known or
Prevalence and persistence of HIV-1 TDR
PLOS ONE | https://doi.org/10.1371/journal.pone.0209605 January 16, 2019 2 / 19
publish, or preparation of the manuscript. Initials of
authors who were receiving funds is not applicable.
Competing interests: The authors have declared
that no competing interests exist.
reliably estimated for each individual taking part. The study was approved by the ethical com-
mittee of the Charité University Medicine Berlin and all study patients enrolled gave written
informed consent. Study patients are categorized as (i) acute seroconverters if the HIV-1 sero-
conversion is confirmed by laboratory diagnostics defined as reactive or undetermined ELISA
followed by incomplete Immunoblot or detectable HIV viral load or (ii) as documented sero-
converters if a maximum interval of three years is given between the last negative and the first
confirmed positive HIV-1 antibody test. The study design and inclusion criteria have been
described previously in detail [24, 25]. The analyses presented here included study patients
enrolled between 30.06.1997 and 18.01.2018.
HIV-1 genotyping
Viral RNA was isolated from plasma samples using the QIAamp Viral RNA Mini Kit (Qiagen,
Hilden, Germany) or by automatic extraction with the NucliSENS easyMAG platform (Bio-
merieux, Nürtingen, Germany). HIV-1 genotyping was performed on extracted RNA using
the ViroSeq HIV-1 Genotyping System (Abbott, Wiesbaden, Germany) with subsequent pop-
ulation-based Sanger sequencing using the BigDye Terminator v1.1 Cycle Sequencing Kit
(Thermo Fisher Scientific, Dreieich, Germany) or an inhouse HIV-1 genotyping assay cover-
ing the protease (PR) and reverse transcriptase (RT) with subsequent population-based Sanger
sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific,
Dreieich, Germany) [26]. Sequence analysis was performed on an ABI Prism 310 capillary
sequencer (Thermo Fisher Scientific, Germany). SeqMan Pro (Lasergene v10.0.1, DNASTAR,
USA) was used to generate the consensus sequence. In addition, some HIV-1 sequences were
provided by participating study centers. HIV-1 subtypes were assessed with the REGA HIV-1
subtyping tool Version 3.0 [27].
Sequences are available at GenBank with accession numbers MH470511 to MH472562 and
as published previously [18, 28].
Data analysis
All baseline HIV-1 genotyping results from ART-naïve study patients were included for the
analysis of the TDR prevalence. TDRMs were defined as mutations that reduce viral suscepti-
bility to antiretroviral drugs (potential low-level resistance, low-level resistance, intermediate
resistance, high-level resistance) according to the SDRM list of the Stanford HIVdb algorithm
version 8.4 [11, 12]. TDRMs for the three major drug classes were studied: nucleoside and
nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhib-
itors (NNRTIs) and protease inhibitors (PIs). A detailed list of TDRMs evaluated in this study
can be found in S1 Table. In addition, analysis of TDR prevalence was performed according to
the WHO SDRM list to enable comparison with TDR prevalence from other countries [10].
Time-trend analyses were performed with STATA SE15 (StataCorp LLC, Texas, USA).
In study patients with TDR, baseline susceptibility to PIs, NRTIs and NNRTIs was analysed
using the Stanford HIVdb algorithm version 8.4 based on all mutations observed at baseline
HIV-1 genotyping, including polymorphic positions [11].
If a TDRM was detected at baseline HIV-1 genotyping, all available HIV-1 genotyping
results during the ART-naïve course of infection of the study patient were screened for the per-
sistence of the TDRM. If the TDRM was lost during follow-up, the time point of loss was
defined as the blood sampling date of the follow-up sample in which the TDRM was no longer
detectable by population-based Sanger sequencing. TDRM persistence was calculated using a
non-parametric Kaplan-Meier approach including either the duration until the TDRM was
lost or the maximal observation time. A Kaplan-Meier plot was generated using Stata SE15
Prevalence and persistence of HIV-1 TDR
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(StataCorp LLC, Texas, USA) showing the cumulative probability of TDRM loss versus the
ART-free time since the date of infection. The mean survival time of TDRMs was estimated as
the area under the survival curve and expressed with a 95% confidence interval (CI). If no loss
of TDRM was observed, the maximal duration of observation was used as an approximation of
the period of persistence of single TDRMs. Follow-up HIV-1 sequences (PR and RT) of each
study patient were confirmed by a cluster analysis using TransmicBS [18] with a bootstrap of
0.95 and a mean pairwise patristic distance of 0.035 on a maximum likelihood phylogenetic
tree generated with IQtree [29].
Results
Sample and patient characteristics
In total, baseline samples of 2715 HIV-1 positive, ART-naïve study patients in the German
HIV-1 Seroconverter Study with known or reliably estimated date of seroconversion between
1996 and 2017 were successfully HIV-1 genotyped (Table 1). The study patients had a calcu-
lated date of seroconversion between the 05 January 1996 and 27 December 2017.
Study patients were mainly male (94.9%), had a median age of 33.0 (IQR 27–39) years at
seroconversion and were infected with HIV-1 subtype B (88.1%), followed by unique recombi-
nant forms (URF, 2.7%) and subtype A1 (2.4%). 40.3% of study patients were acute and 59.7%
documented seroconverters. 53.0% of the documented seroconverters had an estimated date
of seroconversion with less than 12 months between the last negative and first confirmed posi-
tive HIV-1 test.
Prevalence of TDR in the HIV-1 Seroconverter Study Cohort
The overall prevalence of total TDR between 1996 and 2017 (year of seroconversion) was
17.2% (95% CI 15.7–18.6). Transmitted NNRTI resistance was most frequently observed in
the study patients with 7.8% (95% CI 6.8–8.8), followed by 5.0% (95% CI 4.2–5.9) NRTI resis-
tance and 2.8% (95% CI 2.2–3.4) PI resistance. Dual-class resistance was observed in 1.3%
(95% CI 0.9–1.7) of the study patients, while only 0.2% (95% CI 0–0.4) of the study patients
were infected with a triple-class resistant virus (Fig 1).
The prevalence of total TDR (OR = 0.89, p = 0.034, Fig 2A) and of transmitted NRTI resis-
tance (OR = 0.65, p = 0.000, Fig 2B) decreased significantly in our study cohort between 1996
and 2017. In contrast, the prevalence of transmitted NNRTI (OR = 1.01, p = 0.509, Fig 2C)
and PI (OR = 0.93, p = 0.497, Fig 2D) resistance remained stable between 1996 and 2017 with-
out a significant trend.
Univariate logistic regression was performed for the following factors: country of origin,
risk group, sex, age and HIV-1 subtype. Only the factors subtype B versus non-B subtype
(OR = 2.90, p = 0.004) and German origin versus non-German origin (OR = 2.15, p = 0.005)
were significantly associated with a higher risk of transmitted NRTI resistance.
If the analysis was restricted to the last ten year period between 2008 and 2017, no signifi-
cant decline in the prevalence of total TDR (OR = 0.99, p = 0.714) or transmitted resistance to
any drug class was observed (NRTI: OR = 0.95, p = 0.341; NNRTI: OR = 0.99, p = 0.848; PI:
OR = 1.01, p = 0.863).
When applying the WHO SDRM list, the overall prevalence of total TDR was 10.6% (95%
CI 9.5–11.8) in the entire study period (1996–2017) and 8.9% (95% CI 7.4–10.3) in more
recent years (2008–2017). The prevalence for the different drug resistance classes were 5.0%
(95% CI 4.2–5.8) NRTI resistance, 2.4% (95% CI 1.9–3.0) NNRTI resistance, 2.1% (95% CI
2.0–2.7) PI resistance, 0.8% (95% CI 0.5–1.1) dual-class resistance and 0.2% (95% CI 0.0–0.4)
triple-class resistance.
Prevalence and persistence of HIV-1 TDR
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Susceptibility to antiretroviral drugs in the HIV-1 Seroconverter Study
Cohort
The transmitted NRTI resistance mutations observed mostly affected the baseline susceptibility
to didanosine (DDI), stavudine (d4T) and zidovudine (AZT), for which 6.2%, 6.1% and 6.0% of
viruses, respectively, have been predicted to have at least a potential low-level resistance (Fig 3).
However, due to toxicity, all three drugs are no longer recommended in the European ART
guidelines [30] and have not been relevant for first-line regimens in our study cohort since 2003
(DDI, d4T) and 2008 (AZT) (Fig 4A). Predicted resistance to the NRTIs abacavir (ABC), emtri-
citabine (FTC), lamivudine (3TC) and tenofovir (TDF/TAF), which are still recommended, was
limited to a maximum of 2.8% (Fig 3A). Since 2006, FTC and TDF/TAF have been the most
commonly prescribed NRTIs in first-line regimens in our study cohort (Fig 4A).
Table 1. Sample and patient characteristics in the German HIV-1 Seroconverter Study Cohort (1996–2017).
N (%)










High prevalence country 16 (0.6)
Exposure at work 7 (0.3)

















One drug class 425 (91.2)
Two drug classes 35 (7.5)
Three drug classes 6 (1.3)
N: Number; M: Months; MSM: Men who have sex with men; HET: Heterosexual contact; IDU: Intravenous drug
users
https://doi.org/10.1371/journal.pone.0209605.t001
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Fig 1. Overall prevalence of drug resistance classes in the German HIV-1 Seroconverter Study Cohort (1996–2017). Prevalence
with 95% CI are given.
https://doi.org/10.1371/journal.pone.0209605.g001
Fig 2. Prevalence trends of TDR in the German HIV-1 Seroconverter Study Cohort (1996–2017). N(1996–2002) = 296, N(2003–2007) = 985,
N(2008–2012) = 885, N(2013–2017) = 549. A) Prevalence trend for total TDR. B) Prevalence trend for transmitted NRTI resistance. C) Prevalence
trend for transmitted NNRTI resistance. D) Prevalence trend for transmitted PI resistance.
https://doi.org/10.1371/journal.pone.0209605.g002
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The susceptibility to all currently available NNRTIs was highly affected by transmitted
NNRTI resistance mutations, with a predicted resistance of 6.5% to 6.9%. For the second gen-
eration NNRTI etravirine (ETR), a high proportion of 6.3% was predicted to be potentially
low-level resistant only (Fig 3B). However, ETR is not recommended for first-line regimens
[30] and is therefore not frequently used in first-line regimens in our study cohort (Fig 4B).
Resistance to the second generation NNRTI rilpivirine (RPV), which is the only NNRTI rec-
ommended for first-line regimens [30], was mainly caused by low-level resistant viruses carry-
ing polymorphic mutations at position E138. Mutations E138A/G/K/R were found in 99 of
186 viruses (52.9%) showing RPV resistance, which account for 40% of all NNRTI-resistant
viruses. Since its approval in 2011, RPV has become the most common NNRTI for first-line
regimens prescribed in our study cohort (Fig 4B).
Transmitted PI resistance mutations had an overall low impact on the susceptibility to PIs.
The highest resistance rate of 3.5% was observed to the first generation PI nelfinavir (NFV)
(Fig 3C), which is no longer recommended in the European ART guidelines [30] and has not
been relevant for first-line regimens in our study cohort since 2003 (Fig 4C). Among all PIs
still in use [30], the susceptibility of fosamprenavir (FPV) was most affected with 2.9% pre-
dicted resistance. For darunavir (DRV), the only PI recommended for first-line regimens [30],
Fig 3. Predicted resistance to antiretroviral drugs in the German HIV-1 Seroconverter Study Cohort (1996–2017). �: first line-regimen; ��:
no longer recommended in European ART guidelines; /r: ritonavir-boosted; 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T:
stavudine; DDI: didanosine; FTC: emtricitabine; TDF: tenofovir disoproxil fumarate; EFV: efavirenz; ETR: etravirine; NVP: nevirapine; RPV:
rilpivirine; ATV: atazanavir; DRV: darunavir; FPV: fosamprenavir; IDV: indinavir; LPV: lopinavir; NFV: nelfinavir; SQV: saquinavir; TPV:
tipranavir.
https://doi.org/10.1371/journal.pone.0209605.g003
Prevalence and persistence of HIV-1 TDR
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the predicted resistance was only 0.4% (Fig 3C). Among PIs used in first-line regimens in our
study cohort, DRV was also the most prescribed drug since 2010 (Fig 4C),
Persistence of TDRMs in the study cohort
In total, 765 samples of 466 ART-naïve study patients were included in the analysis of persis-
tence of TDRMs. The ART-naïve course of infection was followed in study patients in a range
between 0 and 3730 days with a median of 258 days (95% CI 215–321). Follow-up samples
were available for 146 of the 466 study patients (31.3%), whereas only the baseline sample was
available for the remaining 320 study patients (68.7%). The median time between collections
of follow-up samples was 1.1 years ranging between 10 and 1855 days. Detailed sample and
patient characteristics can be found in Table 2. A total of 700 TDRMs were detected in the 466
baseline samples, of which only 37 TDRMs (5.3%) disappeared during follow-up sampling.
76.6% of viruses harbored one TDRM at baseline (singleton), 13.5% had two TDRMs and
9.7% had three or more TDRMs. The presence of three or more TDRMs was mainly due to the
accumulation of Thymidine-Analogue-Mutations (TAMs: M41L, D67N, K70R, L210W,
T215F/Y, T215 revertants and K219E/Q), which usually occur in mutation patterns [9]. Most
Fig 4. Drugs prescribed in first-line regimens in the German HIV-1 Seroconverter Study Cohort (1996–2017). A total of 2529 study patients
started first-line ART between 1996 and 2017. The proportion of single drugs among all drugs prescribed in first line-regimens per year are
given. N(1996) = 63, N(1997) = 157, N(1998) = 119, N(1999) = 130, N(2000) = 87, N(2001) = 85, N(2002) = 160, N(2003) = 177, N(2004) = 233, N(2005) = 236,
N(2006) = 255, N(2007) = 392, N(2008) = 475, N(2009) = 497, N(2010) = 596, N(2011) = 592, N(2012) = 639, N(2013) = 684, N(2014) = 543, N(2015) = 565,
N(2016) = 505, N(2017) = 303. A) NRTIs in first-line regimens. 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DDC:
zalcitabine; DDI: didanosine; FTC: emtricitabine; TAF: tenofovir alafenamide fumarate; TDF: tenofovir disoproxil fumarate. B) NNRTIs in first-
line regimens. EFV: efavirenz; ETR: etravirine; NVP: nevirapine; RPV: rilpivirine. C) PIs in first-line regimens. ATV: atazanavir; DRV:
darunavir; FPV: fosamprenavir; IDV: indinavir; LPV: lopinavir; NFV: nelfinavir; RTV: ritonavir; SQV: saquinavir. D) Integrase inhibitors (INIs)
in first-line regimens. RAL: raltegravir; EVG: elvitegravir; DTG: dolutegravir.
https://doi.org/10.1371/journal.pone.0209605.g004
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viruses (91.2%) were resistant to one drug class, with only 7.5% and 1.3% showing resistance
against two and three drug classes, respectively.
The most common TDRMs found in baseline samples were the T215 revertants, followed
by E138A/G/K/Q/R, K103NS, V179DE and M41L (S1 Table). In total, TDRMs at 46 positions
in PR and RT were analysed. For a number of TDRMs, no loss could be observed during the
observation period (S1 Table) and, according to their maximal duration of observation, the fol-
lowing TDRMs seem to survive for lengthy periods in the absence of ART: the NRTI resistance
mutations D67N (5.9 years), K70R (6.9 years), F77L (10.2 years), T215E (5.9 years) and K219Q
(5.9 years), the NNRTI resistance mutations A98G (6.5 years) and Y188L (5.9 years) as well as
the PI mutations I54L (5.9 years) and L90M (8.4 years) (S1 Table).
A Kaplan-Meier analysis could be performed for 18 TDRMs (K20T, L23I, K43T, M46I/L/V,
I54V, M41L, L74I, M184V, L210W, K219R, T215A/C/D/N/S and T215Y). Within the different
drug classes, transmitted NRTI mutations persisted for a mean of 1.0 to 6.4 years, NNRTI
mutations 1.5 to 8.0 years and PI mutations 1.0 to 5.1 years (Fig 5A–5C).
The NNRTI mutations at position E138 (E138A/G/K) had the longest mean Kaplan-Meier
estimates (8.0 years, 95% CI 5.8–10.2 / 7.9 years, 95% CI 5.4–10.3 / 6.7 years, 95% CI 6.7–6.7)











High prevalence country 3 (0.6)














One mutation 357 (76.6)
Two mutations 63 (13.5)
Three or more mutations 45 (9.7)
N: Number; M: Months; MSM: Men who have sex with men; HET: Heterosexual contact; IDU: intravenous drug
users.
https://doi.org/10.1371/journal.pone.0209605.t002
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compared to all other TDRMs observed in this study cohort. Similarly, the NRTI resistance
mutation M41L (6.4 years, 95% CI 6.0–6.7) and the NNRTI resistance mutation K103N (5.3
years, 95% CI 4.2–6.5) persisted for a long period. At NRTI position T215, the mean survival
time varied with the specific substitution: T215D and T215S persisted for 4.7 (95% CI 4.4–5.1)
and 4.2 (95% CI 3.5–5.1) years, respectively, while T215A and T215N persisted only for 1.6 (95%
CI 1.1–2.2) and 1.0 (95% CI 1.0–1.0) years, respectively. Likewise, at PI position M46, the mean
Kaplan-Meier estimate ranged from 3.1 to 4.2 years depending on the specific substitution. The
shortest mean survival time of 1.0 year was determined for the PI resistance mutation K20T and
the NRTI resistance mutation T215N (K20T 95% CI 0.6–1.4, T215N 95% CI 1.1–2.2).
Discussion
In this study we present data on the prevalence of TDR between 1996 and 2017 and the persis-
tence of single TDRMs in drug-naïve HIV-1 infected individuals enrolled in the German HIV-
1 Seroconverter Study. With the large sample size of 2715 individuals included between 1996
and 2017, our data reliably display the long-term time trend of TDR in Germany. However,
due to the high awareness of HIV-1 in MSM, which leads to frequent testing and therefore
early diagnosis, this group is over-represented in our study cohort. At the same time, this also
results in an under-representation of non-B subtypes, which are mainly detected in heterosex-
ual individuals and individuals from countries of high HIV prevalence [31, 32] who are less
likely to be eligible for our study due to their later diagnoses and missing information about
the last negative test. Molecular surveillance data on HIV-1 in Germany with a higher percent-
age of non-MSM are available from recent years [19, 23]. However, it will become increasingly
Fig 5. Mean survival times of TDRMs during ART-naïve course of infection. Mean Kaplan-Meier estimates with 95% CI are given.
Different mutations occurring at the same position are shown in blue. A) TDRMs affecting NRTIs. B) TDRMs affecting NNRTIs. C) TDRMs
affecting PIs.
https://doi.org/10.1371/journal.pone.0209605.g005
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difficult in the future to acquire samples from patients with a known time point of infection
and a long ART-naïve course of infection (as was possible with the German HIV-1 Serocon-
verter Study) because individuals often now commence virus-suppressing ART directly after
diagnosis [30], making it difficult to address questions as the persistence of TDRMs.
Between 1996 and 2017, the overall prevalence of TDR in the German HIV-1 Seroconverter
Study was 17.2% according to the Stanford HIVdb algorithm SDRM list [11, 12] and 10.6%
according to the WHO SDRM list [10], which is in line with other European TDR studies cov-
ering comparable periods of time [33–37]. In particular, within the European surveillance pro-
gram SPREAD, which includes newly infected individuals from 26 European countries, a TDR
rate of around 9% has been observed since 2002 [38–41]. Likewise, an overall TDR prevalence
of 11% was determined between 1996 and 2012 in the CASCADE collaboration in EuroCoord,
which mostly includes HIV-1 seroconverters from Europe [42]. Different temporal trends for
the prevalence of TDR and the single drug classes were observed in different study populations
and over different time periods. In the present analysis we observed a decreasing trend in the
overall prevalence of TDR between 1996 and 2017, which has not been apparent in the previ-
ous analysis covering the years between 1996 and 2010 [24]. The generally decreasing long-
term but (in recent years) stable trend of TDR observed in our study cohort was also noticed
in the large CASCADE analysis [42]. Genotypic resistance testing is therefore still important
and should be continued (i) at the patient level before initiation of first-line ART and (ii) at the
population level for molecular surveillance purposes. As the prevalence of ADR has been
decreasing in developed countries for several years [34, 43], a main driver of the stable TDR
rate appears to be onward transmission from ART-naïve individuals [35, 44–46]. We and oth-
ers found that forward transmission occurs preferably early after infection when individuals
are probably still unaware of their HIV-1 positivity and have high viral loads [18, 47–49]. Pub-
lic health efforts should therefore be undertaken to facilitate earlier diagnosis and antiretroviral
treatment to prevent onward transmission. Data from the German ClinSurv HIV Cohort
showed that once initiated, ART is highly effective, with viral loads being successfully sup-
pressed in 93% of study patients [50]. Therefore, the greatest potential for improvement indeed
lies in the first two columns of the treatment cascade, namely early diagnosis and treatment,
both of which currently have a coverage of 86% in Germany [51].
The proportion of transmitted NNRTI resistance in our study cohort was 7.8% according
to the Stanford HIVdb algorithm SDRM list but only 2.4% according to the WHO SDRM list.
The approximately 3-fold higher prevalence of NNRTI mutations based on the Stanford
HIVdb algorithm SDRM list is mainly due to the polymorphic NNRTI mutations at position
E138 that are not included in the WHO SDRM list. In our study cohort, NNRTI mutations at
position E138 were found in 40% of all individuals with NNRTI resistance. Indeed, NNRTI
resistance mutations affected the predicted baseline susceptibility to currently recommended
first-line regimens the most. Current first-line regimens in Germany consist of a backbone of
two NRTIs (TDF/TAF, FTC, ABC or 3TC) in combination with one NNRTI (RPV), one PI
(DRV) or one INI (RAL, EVG, DTG) [30]. For the NNRTI RPV recommended for first-line
regimens [30], the baseline susceptibility was predicted to be reduced in our study cohort,
mainly due to the NNRTI-associated polymorphic resistance mutations E138A/G/K/R. These
findings are in line with the results obtained by the large SPREAD study [41]. This underscores
the need for HIV-1 genotypic resistance testing prior to the start of a first-line regimen. As the
susceptibility of RPV is more often affected by baseline resistance than DRV or INIs [52], a
combination of two NRTIs with DRV or RAL/EVG/DTG might be preferred. Indeed, our data
concerning prescribed first-line regimens in the HIV-1 German Seroconverter Study Cohort
showed that DTG has been most often used since 2014 (Fig 4D). It has recently been shown
that the mutations E138K and M184I can mutually compensate for each other, resulting in
Prevalence and persistence of HIV-1 TDR
PLOS ONE | https://doi.org/10.1371/journal.pone.0209605 January 16, 2019 11 / 19
restoration of viral replication capacity [53]. As the combination of RPV, FTC and TDF is
approved as a single-tablet regimen (Eviplera), with RPV selecting for E138 mutations and
FTC selecting for the M184I mutation, the emergence of E138 mutations, especially in combi-
nation with M184I, has to be monitored more closely in the future [54, 55].
Until now, studies into the persistence of TDRMs have been scarce. Nevertheless, three
studies have performed survival analyses of single TDRMs or TDRM groups in patient cohorts
of 75, 168 and 313 individuals [15–17]. In our study, 466 individuals with a known duration
between infection and plasma sampling for HIV-1 genotyping could be included in the analy-
sis of TDRM persistence in the absence of selective drug pressure. The longest mean survival
times of approximately 8 years were observed for the NNRTI mutations E138A/G/K. Competi-
tion experiments have shown that E138A/G are the substitutions with the highest fitness, fol-
lowed by E138R/K/Q, which is in line with the long mean persistence times found in our study
[56]. Data on the in vivo persistence of E138 mutations have not so far been published, but
NNRTI mutations generally have a low overall impact on viral fitness and are therefore
expected to persist for a long time when transmitted [9, 16, 17]. Indeed, among the NNRTI
mutations transmitted, the mutations K103N and G190A also showed long mean survival
times of 5.3 (95% CI 4.2–6.5) and 3.8 years (95% CI 2.8–4.8), respectively, which agrees with
the results from the three other cohort studies [15–17]. The K103N mutation, causing high
resistance to the first generation NNRTI drugs NVP and EFV that are recommended for sec-
ond-line regimens in Europe [30], was also frequently observed in our study cohort.
In general, transmitted PI resistance mutations tend to persist regardless of their reduced
replication capacity due to fixation through fitness compensating polymorphisms [6, 9]. In
concordance with the three other studies on the persistence of TDRMs [15–17], for most PI
mutations (I54V, K43T, L23I, M46I/L/V) a long mean survival time between 2.2 and 4.2 years
was found in our study cohort, with the exception of K20T that had a mean survival time of
one (95% CI 0.4–1.2) year. We could not obtain a Kaplan-Meier estimate for L90M, but persis-
tence of L90M was observed in one study patient followed for 8.4 years. This is in line with the
data from Castro et al. and Yang et al. who observed persistence of L90M for up to 5.1 years
[15, 17].
In our study cohort, the NRTI mutations M41L, L210W, T215C/D/S and K219R, which
also occurred in high frequencies among the transmitted NRTI mutations, had calculated
mean survival times of between 2.9 and 6.4 years. In contrast, the mean survival times deter-
mined for NRTI mutations T215Y/A/N and L74I, which were also found at a lower proportion
among the transmitted NRTI mutations, ranged from 1.0 to 1.7 years. Although we could not
obtain a Kaplan-Meier estimate for the mutation F77L, we did observe the mutation for 10.2
years in one study patient, the longest follow-up time for any TDRM in our cohort. Unfortu-
nately, persistence data for this mutation are not available from other studies. Moreover, the
mutations K70R and D67N were observed in one study patient each for 6.9 and 5.9 years,
respectively. D67N has been shown in other studies to persist for a long time, while K70R has
been shown to be lost rather quickly [15, 17]. However, the long persistence of K70R in our
study was observed in a patient without additional TDRMs. It has been shown in vitro that the
fitness cost of K70R is higher in combination with other mutations, possibly explaining its
faster reversion in other in vivo cohort studies [5, 15, 17]. Overall, the persistence times of
transmitted NRTI mutations also varied substantially but with a similar pattern in the three
other studies addressing the persistence of TDRMs [15–17]. One exception was the long mean
persistence time of 3.2 years (95% CI 1.9–5.4) of the M184V mutation in our study population,
which is in contrast to the rapid loss observed in all other in vivo persistence studies [9, 15–17].
The most likely reason is that one study patient was included who lost the M184V mutation
during an interval of 3.1 years between two plasma samplings. This leads to an overestimation
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of the mean survival time and is also reflected by the high 95% confidence interval of the mean
Kaplan-Meier estimate. Despite the decreasing trend in transmitted NRTI resistance, which is
probably due to decreasing acquired NRTI resistance, the overall prevalence of transmitted
NRTIs in our study cohort was high and study patients of German origin infected with a sub-
type B virus had a higher risk of being infected with a NRTI-resistant strain. These findings are
plausible given the potential for long persistence observed for several transmitted NRTI muta-
tions and the further transmission soon after infection [18]. This is particularly true in light of
the fact that subtype B is the most common HIV-1 subtype in Germany and that NRTIs were
the first approved antiretroviral drugs in Germany, applied as monotherapy and therefore
with a low genetic barrier to drug resistance, until the release of the first NNRTIs and PIs in
1996.
The results of our study and the studies of Castro et al. [15], Yang et al. [17] and Jain et al.
[16] are not directly comparable because of differences in (i) the methodological approaches
used to calculate survival times, (ii) the characteristics of the study populations and (iii) the
sampling schemes and durations of observation. Nevertheless, a similar trend towards the sur-
vival times of single TDRMs is obvious in all studies. The fact that identical TDRMs with
remarkably long persistence times have been observed in all four studies further supports the
need of baseline genotypic resistance testing. Fortunately, according to the current treatment
guidelines [30], only one drug—the NNRTI RPV—was significantly affected by long-term per-
sisting TDRMs. Persisting transmitted NRTI mutations causing high levels of resistance
affected NRTIs (DDI, d4T, AZT) that are no longer in use. Continued onward transmission of
drug-resistant HIV-1 harboring persisting TDRMs might lead to the appearance of a new
“wildtype” that is resistant to previously but not currently used drugs.
One major limitation of our study remains the irregular collection of plasma samples from
study patients despite samples being generally requested on an annual basis and the median
time between follow-up samples being only 0.7 years in our study cohort. An extended time
between sampling can lead to an overestimation of the mean survival time, especially for muta-
tions with short persistence as we have proposed for M184V. This might also be the case for
mutations E138A, M46I, M46V and T215S, because for these TDRMs there was a period of
more than 2.5 years between samples collected with and without the corresponding mutation.
A further limitation of our study is the fact that only the baseline sample was available for a
large number of individuals (68.7%), lowering the calculated median observation time in per-
son years compared to the longest observation time in years per TDRM. Small median obser-
vation times therefore do not predict short persistence times but rather reflect the high
number of individuals without a follow-up sample. Short observation periods together with a
presumed low prevalence [52] were also the reason for not analysing TDRMs affecting inte-
grase inhibitors.
A final limitation of our study was the use of population-based Sanger sequencing for geno-
typic resistance testing, an approach unable to detect HIV-1 drug resistant variants at levels
below approximately 20% [57]. It has previously been shown that using ultrasensitive assays
reveals a much higher prevalence of TDRMs [58], as mutations with high fitness costs might in
particular decay to low-levels by the time of HIV-1 diagnosis [59]. In our study, viruses with a
single drug resistance mutation (singletons) were highly prevalent, and it is therefore conceiv-
able that ultradeep sequencing might reveal the presence of further TDRMs, leading to an
underestimation of the calculated survival rates as well as the TDR prevalence as other studies
suggest [58, 60]. Nevertheless, despite using ultradeep sequencing other studies failed to find
additional TDRMs [61, 62]. The impact of minority drug resistant variants on treatment suc-
cess is therefore still a matter of debate as conflicting results have been observed in different
studies [63].
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Our data on TDR prevalence in Germany are in concordance with other studies from
Europe. The stable prevalence of TDR in the last ten years in combination with the long persis-
tence of single TDRMs found in this study indicates the onward transmission of TDR from
ART-naïve individuals rather than from individuals with a history of ART as the main driver
of TDR. Early diagnosis and antiretroviral treatment of HIV-1 infections are therefore
required to prevent the spread of drug-resistant HIV-1. The high prevalence of NNRTI muta-
tions at polymorphic position E138, which affect susceptibility to RPV and which had mean
survival times of up to 8 years, already suggests that first-line regimens combining two NRTIs
with DTG is preferred in our study cohort.
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